Obstructive UropathyNCT07855666
Safety and Efficacy of Ultrasound-Guided Percutaneous Nephrostomy in Oncology Patients
A study testing Ultrasound-guided percutaneous nephrostomy in people with Obstructive Uropathy and Hydronephrosis, run by Assiut University.
Trial summary
Obstructive uropathy is a serious complication frequently seen in cancer patients, occurring when urine flow from the kidneys is blocked by tumor compression, invasion, or benign etiologies such as radiation-induced strictures and stones. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obstructive Uropathy, Hydronephrosis, Ureteral Obstruction
- What is being tested?
- Ultrasound-guided percutaneous nephrostomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- Nov 2026to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with known or suspected primary malignancy.
- Confirmed ureteric obstruction on diagnostic imaging (ultrasound or CT), whether due to malignant etiology (e.g., extrinsic tumor compression or direct invasion) or benign etiology (e.g., calculi, radiation-induced stricture, or iatrogenic injury).
- Clinical or biochemical evidence of acute renal impairment or symptomatic hydronephrosis necessitating urgent or elective decompression.
Who cannot join
- Patients who refuse the intervention or withdraw consent.
- Patients undergoing simultaneous retrograde or antegrade ureteric stent placement during the same procedure.
- Patients with uncorrectable coagulopathy (abnormal PT/INR or severe thrombocytopenia).
- Strict medical contraindications to percutaneous interventions.
About this study
Obstructive uropathy is a serious complication frequently seen in cancer patients, occurring when urine flow from the kidneys is blocked by tumor compression, invasion, or benign etiologies such as radiation-induced strictures and stones. If left untreated, this blockage leads to hydronephrosis, acute kidney impairment, and interruptions in cancer therapy. When internal ureteral stenting fails or is not possible, percutaneous nephrostomy (PCN), which involves inserting a small drainage tube through the back directly into the renal collecting system, is required to decompress the kidney and preserve renal function.
Traditionally, PCN is performed under fluoroscopy, exposing patients and healthcare staff to ionizing radiation. Ultrasound guidance provides continuous real-time visualization of the renal structures while completely eliminating radiation hazards.
Read more
The primary purpose of this prospective interventional study is to evaluate the technical success, safety, and complication rates of ultrasound-guided percutaneous nephrostomy in oncology patients presenting with urinary tract obstruction.
Participants in this study undergo ultrasound-guided PCN under local anesthesia using the standard Seldinger technique to place an 8Fr pigtail drainage catheter. The study evaluates the technical success rate of the procedure, procedural and post-procedural complications (such as bleeding or sepsis), recovery of kidney function measured by changes in serum creatinine levels, and hospital length of stay.
- Conditions
- Obstructive Uropathy, Hydronephrosis, Ureteral Obstruction, Acute Kidney Injury, Neoplasms
- Being tested
- Ultrasound-guided percutaneous nephrostomy
- Keywords
- Percutaneous Nephrostomy, Ultrasound Guidance, Interventional Radiology, Renal Decompression, Malignant Ureteral Obstruction, Seldinger Technique
- Medical subject headings
- Hydronephrosis, Ureteral Obstruction, Acute Kidney Injury, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound-guided percutaneous nephrostomyProcedure or surgery
Ultrasound-guided placement of a percutaneous nephrostomy (PCN) catheter using the standard Seldinger technique. Under local anesthesia (1% or 2% lidocaine) and continuous real-time ultrasound visualization without fluoroscopy, access to the dilated pelvicalyceal system is achieved via posterolateral puncture targeting a lower pole posterior calyx using an 18-gauge needle (or 21/22-gauge Chiba needle). A 0.035-inch or 0.038-inch J-tip guidewire is advanced and coiled within the renal pelvis. The tract is serially dilated over the guidewire using sequential fascial dilators, followed by insertion of an 8Fr locking pigtail nephrostomy catheter into the renal collecting system. Proper intrapelvic positioning is confirmed sonographically and via free drainage of urine. The catheter is locked, sutured to the skin with non-absorbable sutures, dressed sterilely, and connected to an external gravity drainage bag.
| Study group | Role | What they receive |
|---|---|---|
| Ultrasound-Guided Percutaneous Nephrostomy | Experimental | Participants with known or suspected primary malignancy presenting with ureteric obstruction undergo ultrasound-guided percutaneous nephrostomy (PCN) using the standard Seldinger technique. Under local anesthesia and real-time ultrasound guidance, percutaneous access to the collecting system (targeting a lower pole posterior calyx) is achieved using an 18-gauge puncture needle (or 21/22-gauge Chiba needle). A 0.035-inch or 0.038-inch J-tip guidewire is advanced into the renal pelvis, followed by serial fascial dilation and placement of an 8Fr locking pigtail nephrostomy catheter connected to external gravity drainage. Receives: Procedure: Ultrasound-guided percutaneous nephrostomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Technical Success Rate of Ultrasound-Guided Percutaneous Nephrostomy
Percentage of procedures resulting in successful puncture and placement of an 8Fr locking pigtail nephrostomy catheter into the renal pelvicalyceal system using ultrasound guidance alone, confirmed by free drainage of urine and post-procedure imaging (ultrasound or KUB radiograph).
Measured: 24 hours post-procedure
Incidence of Procedure-Related Complications
Percentage of participants experiencing procedural or post-procedural complications, including major adverse events (severe retroperitoneal hemorrhage, urosepsis) and minor adverse events (persistent hematuria, tube displacement, or local puncture site infection).
Measured: 2 weeks post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2026
- Study startNov 2026 (estimated)
- Primary completionNov 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obstructive UropathyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed EssamEldin Ali Mahmoud, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07855666
- Sponsor's protocol ID
- US-Guided PCN in Oncology
- Status last verified
- Sep 2026
- First submitted
- 28 Sep 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Efficacy of Ultrasound-Guided Percutaneous Nephrostomy in Oncology Patients
- ClinicalTrials.gov ID
- NCT07855666
- Acronym / sponsor ID
- US-Guided PCN in Oncology
- Conditions
- Obstructive Uropathy, Hydronephrosis, Ureteral Obstruction, Acute Kidney Injury, Neoplasms
- Keywords
- Percutaneous Nephrostomy, Ultrasound Guidance, Interventional Radiology, Renal Decompression, Malignant Ureteral Obstruction, Seldinger Technique
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Nov 2026 (estimated)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 2 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obstructive uropathy is a serious complication frequently seen in cancer patients, occurring when urine flow from the kidneys is blocked by tumor compression, invasion, or benign etiologies such as radiation-induced strictures and stones. If left untreated, this blockage leads to hydronephrosis, acute kidney impairment, and interruptions in cancer therapy. When internal ureteral stenting fails or is not possible, percutaneous nephrostomy (PCN), which involves inserting a small drainage tube through the back directly into the renal collecting system, is required to decompress the kidney and preserve renal function.
Traditionally, PCN is performed under fluoroscopy, exposing patients and healthcare staff to ionizing radiation. Ultrasound guidance provides continuous real-time visualization of the renal structures while completely eliminating radiation hazards.
The primary purpose of this prospective interventional study is to evaluate the technical success, safety, and complication rates of ultrasound-guided percutaneous nephrostomy in oncology patients presenting with urinary tract obstruction.
Participants in this study undergo ultrasound-guided PCN under local anesthesia using the standard Seldinger technique to place an 8Fr pigtail drainage catheter. The study evaluates the technical success rate of the procedure, procedural and post-procedural complications (such as bleeding or sepsis), recovery of kidney function measured by changes in serum creatinine levels, and hospital length of stay.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Ultrasound-Guided Percutaneous Nephrostomy | Experimental | Procedure: Ultrasound-guided percutaneous nephrostomyParticipants with known or suspected primary malignancy presenting with ureteric obstruction undergo ultrasound-guided percutaneous nephrostomy (PCN) using the standard Seldinger technique. Under local anesthesia and real-time ultrasound guidance, percutaneous access to the collecting system (targeting a lower pole posterior calyx) is achieved using an 18-gauge puncture needle (or 21/22-gauge Chiba needle). A 0.035-inch or 0.038-inch J-tip guidewire is advanced into the renal pelvis, followed by serial fascial dilation and placement of an 8Fr locking pigtail nephrostomy catheter connected to external gravity drainage. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients with known or suspected primary malignancy.
- Confirmed ureteric obstruction on diagnostic imaging (ultrasound or CT), whether due to malignant etiology (e.g., extrinsic tumor compression or direct invasion) or benign etiology (e.g., calculi, radiation-induced stricture, or iatrogenic injury).
- Clinical or biochemical evidence of acute renal impairment or symptomatic hydronephrosis necessitating urgent or elective decompression.
Key exclusion criteria (4 listed)
- Patients who refuse the intervention or withdraw consent.
- Patients undergoing simultaneous retrograde or antegrade ureteric stent placement during the same procedure.
- Patients with uncorrectable coagulopathy (abnormal PT/INR or severe thrombocytopenia).
- Strict medical contraindications to percutaneous interventions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound-guided percutaneous nephrostomyUltrasound-guided placement of a percutaneous nephrostomy (PCN) catheter using the standard Seldinger technique. Under local anesthesia (1% or 2% lidocaine) and continuous real-time ultrasound visualization without fluoroscopy, access to the dilated pelvicalyceal system is achieved via posterolateral puncture targeting a lower pole posterior calyx using an 18-gauge needle (or 21/22-gauge Chiba needle). A 0.035-inch or 0.038-inch J-tip guidewire is advanced and coiled within the renal pelvis. The tract is serially dilated over the guidewire using sequential fascial dilators, followed by insertion of an 8Fr locking pigtail nephrostomy catheter into the renal collecting system. Proper intrapelvic positioning is confirmed sonographically and via free drainage of urine. The catheter is locked, sutured to the skin with non-absorbable sutures, dressed sterilely, and connected to an external gravity drainage bag. | Procedure or surgery | Ultrasound-Guided Percutaneous Nephrostomy |
Primary outcome
Technical Success Rate of Ultrasound-Guided Percutaneous Nephrostomy
Time frame: 24 hours post-procedure
Percentage of procedures resulting in successful puncture and placement of an 8Fr locking pigtail nephrostomy catheter into the renal pelvicalyceal system using ultrasound guidance alone, confirmed by free drainage of urine and post-procedure imaging (ultrasound or KUB radiograph).
Incidence of Procedure-Related Complications
Time frame: 2 weeks post-procedure
Percentage of participants experiencing procedural or post-procedural complications, including major adverse events (severe retroperitoneal hemorrhage, urosepsis) and minor adverse events (persistent hematuria, tube displacement, or local puncture site infection).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
Related trials for Obstructive Uropathy
RecruitingPhase 1
Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia
Renal Failure Congenital, Congenital Renal Anomaly Nos
RecruitingPhase 1/2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Autoimmune Disorders, Systemic Sclerosis
Not yet recruiting
Using Community Health Workers to Support Rural Care Partners of Seriously Ill Older Veterans
Dementia, Cancer
Not yet recruitingObservational study
Long-Term Effectiveness and Safety of Sacral Neuromodulation With InterStim for Lower Urinary Tract Dysfunction
Overactive Bladder (OAB), Urgency Urinary Incontinence
RecruitingObservational study
Standardized Prenatal Clinical Care for LUTO
Urethral Obstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Ultrasound-guided percutaneous nephrostomy in people with Obstructive Uropathy and Hydronephrosis, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Technical Success Rate of Ultrasound-Guided Percutaneous Nephrostomy (time frame: 24 hours post-procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.